CG
PMVP icon

Cutler Group’s PMV Pharmaceuticals PMVP Stock Holding History

Cutler Group’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,200
Closed -$2K – 4171
2023
Q3 		$2K Buy
+4,200
New +$28.9K ﹤0.01% 3313
2021
Q3 		– Sell
-2,600
Closed -$3K – 6216
2021
Q2 		$3K Buy
+2,600
New +$86.8K ﹤0.01% 4810

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Cutler Group's PMVP Position: Q1 2024 in Review

Cutler Group held its PMV Pharmaceuticals (PMVP) position steady in Q1 2024 at 2,500 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1644.

Cutler Group first reported a position in PMVP in Q2 2022 and has held it in 8 quarters since. The position peaked at $179K in Q2 2022. 99 funds tracked by Wall St. Rank hold PMVP as of Q1 2024.

  • Cutler Group held 2,500 shares of PMV Pharmaceuticals worth $4K as of Q1 2024.
  • Cutler Group left its PMV Pharmaceuticals share count unchanged in Q1 2024.
  • PMV Pharmaceuticals made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1644 holding.
  • Cutler Group first reported a position in PMV Pharmaceuticals in Q2 2022 and has held it in 8 quarters since.
  • Cutler Group's PMV Pharmaceuticals position peaked at $179K in Q2 2022.
  • 99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.